Mitsubishi Gas Forms Asian Biologics CRO Partnership with Catalent
January 21, 2015 at 06:06 AM EST
Mitsubishi Gas Chemical Company of Tokyo entered an Asian CRO biologics partnership with US-based Catalent Pharma. Using its GPEx® technology, Catalent will engineer cell lines for the partnership's clients, and MGC Pharma will provide Phase III and commercial manufacturing. In addition, MGC will use the GPEx technology to offer biosimilar cell lines to clients. More details.... Stock Symbol: (NYSE: CTLT) Share this with colleagues: // //